Prenetics Global Limited
NASDAQ:PREMedical - Diagnostics & Research
+$0.43 today
- Market cap
- $185.61M
- Beta
- 0.24
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$4.18
Volume 1.58M
Average 0.22M
PRE Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Prenetics Global LimitedNASDAQ: PRE
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $23.11M (cash outflow) rose 122.4% year over year, ahead of the +35.9% change in trailing-twelve-month net income. Sequentially, it rose 2.7% from the prior quarter. Over 3 fiscal years it compounded at -34.8% a year.
Context
- Net income amounted to 57.0% of revenue in FY2025, down 105.6 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 8 analysts of -$55.3M (+4.9%) for the fiscal year ending Dec 2026, a pace similar to FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$23.11M+2.7% QoQ
- Last fiscal yearDec 2025
- -$52.7M+5.8% YoY
- LTMMar 2026
- -$65.41M+35.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +122.4% | +16.9% | -105.5 pp |
| 1 year | +5.8% | +4.9% | -0.9 pp |
| 3-year CAGR | -34.8% | -25.7% | +9.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (52.7M) USD
- Year-over-year change
- -5.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (52.7M) | -5.8% |
| FY2024 | 2024-12-31 | (49.81M) | +23.1% |
| FY2023 | 2023-12-31 | (64.78M) | +66.0% |
| FY2022 | 2022-12-31 | (190.45M) | -9.4% |
| FY2021 | 2021-12-31 | (174.02M) | — |
Net Income vs competitors
How PRE compares with its peers on the latest reported figures
- PRE's LTM Mar 2026 net income of $65.41M is the 4th largest of the 11 companies compared; the peer median is $43.52M.
- Its year-over-year change of +35.9% is the 4th highest of 11, against a peer median of -3.0%.
- Net income amounts to 57.5% of revenue for PRE, versus a peer median of 92.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $282.61M | +66241.3% | +67.6% | 9554.2% | |
| LTM Mar 2026 | $123.33M | +55.2% | -13.9% | 356.9% | |
| LTM Mar 2026 | $71.83M | +124.8% | -84.4% | 63.6% | |
| LTM Mar 2026 | $65.41M | +35.9% | -34.8% | 57.5% | |
ATLNAtlantic International Corp. | LTM Dec 2025 | $59.43M | -56.1% | +143.9% | 13.6% |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $47.84M | -17.8% | -11.7% | 2454.6% |
| LTM Mar 2026 | $39.2M | +21.2% | +14.1% | 207.7% | |
| LTM Mar 2026 | $39.12M | -6.4% | +23.7% | 121.2% | |
| LTM Mar 2026 | $37.52M | -22.7% | +1.7% | 24.7% | |
| LTM Mar 2026 | $31.99M | -57.0% | +9.4% | 41.0% | |
| LTM Mar 2026 | $27.31M | +0.4% | -6.0% | 60.9% | |
| Peer median (excluding PRE) | $43.52M | -3.0% | +5.6% | 92.4% | |
Competitors are the stored peer set for PRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (174.02M) | (190.45M) | (64.78M) | (49.81M) | (52.7M) |
| Depreciation & Amortization | 7.35M | 7.54M | 7.79M | 5.93M | 3.78M |
| Deferred Income Tax | 3.73M | 7.15M | (385.84K) | (7.87M) | 0 |
| Stock-Based Compensation | 22.49M | 31.58M | 10.59M | 11.98M | 0 |
| Change in Working Capital | (6.59M) | (33.76M) | 24.21M | 1.97M | 6.62M |
| Accounts Receivables | (24.06M) | 6.97M | 37.63M | (428K) | (529K) |
| Inventory | (2.33M) | 1.26M | (1.73M) | 1.32M | (3.38M) |
| Accounts Payables | (3.46M) | (2.63M) | (5.62M) | (4.68M) | 4.91M |
| Other Working Capital | 23.26M | (39.36M) | (6.08M) | 5.75M | 5.62M |
| Other Non-Cash Items | 160.45M | 192.46M | 8.8M | 8.93M | 20.48M |
| Operating Cash Flow | 13.42M | 14.51M | (13.76M) | (28.87M) | (21.81M) |
| Capital Expenditures | (11.41M) | (6.34M) | (911.81K) | (1.07M) | (208K) |
| Acquisitions (Net) | 0 | (3.42M) | 0 | 21.65M | 37.78M |
| Purchases of Investments | (10M) | (39.92M) | (26M) | (129K) | (20M) |
| Sales of Investments | 0 | 3M | 19.92M | 16M | 0 |
| Other Investing Activities | (3.47M) | 531.99K | (76.52M) | 2.02M | 1,000K |
| Investing Cash Flow | (22.02M) | (46.14M) | (82.95M) | 38.54M | (35.79M) |
| Debt Repayment | (1.3M) | (1.88M) | (3.23M) | (2.56M) | 40.15M |
| Common Stock Issued | 0 | 116.86K | 2.17K | 0 | 2K |
| Common Stock Repurchased | 0 | (661.52K) | (1.23M) | (577K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.65M | 145.86M | (241.5K) | (203K) | (2.61M) |
| Financing Cash Flow | 29.32M | 143.32M | (4.7M) | (3.34M) | 37.54M |
| Effect of Forex Changes | 87.21K | (317.47K) | 467.93K | 221K | (65K) |
| Net Change in Cash | 20.8M | 111.37M | (100.95M) | 6.55M | (20.12M) |
| Free Cash Flow | 2M | 8.17M | (14.68M) | (29.94M) | (22.02M) |
Prenetics Global Limited
NASDAQ:PRE
Intrinsic Alpha fair value
Locked
Current Price
$10.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.